Cartesian Therapeutics Inc
RNAC
Get informed when a big investor buys or sells
+ FollowMarket Cap$294.99M
Close$
$3.67
60.1% downside
Current Fair Value
60.1% downsideOvervalued by 60.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $294.99 Million |
|---|---|
| Enterprise Value | $165.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.57 |
| Outstanding Shares | 29,467,130 |
Return
| Return on Equity | 122.93% |
|---|---|
| Return on Assets | -48.31% |
| Return on Invested Capital | -10.67% |
Valuation & Multiples
| P/E Ratio | -1.69 |
|---|---|
| PEG | 12.42 |
| Price to Sales | - |
| Price to Book Ratio | -1.84 |
| Enterprise Value to Revenue | 111.84 |
| Enterprise Value to EBIT | -5.19 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$179,667
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$150,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 84.85% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.53%▲ 7.66% |
|---|---|
| Total Invested | $43.93M▲ 18.04% |
| Investors Holding | 82▲ 12.00% |
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...